Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.

Identifieur interne : 000299 ( PubMed/Checkpoint ); précédent : 000298; suivant : 000300

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.

Auteurs : Sivan M. Bokobza [Royaume-Uni] ; Yanyan Jiang ; Anika M. Weber ; Aoife M. Devery ; Anderson J. Ryan [Royaume-Uni]

Source :

RBID : pubmed:24946858

Descripteurs français

English descriptors

Abstract

Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the responses are usually incomplete. In this study we show that AKT inhibition, most importantly AKT2 inhibition, synergises with EGFR TKI inhibition to increase cell killing in EGFR M+ NSCLC cells. However, our data also suggest that the synergistic pro-apoptotic effects may be stunted due to a prosurvival autophagy response induced by AKT inhibition. Consequently, inhibiting autophagy with chloroquine significantly enhanced tumor cell death induced by gefitinib and AKT inhibitors in EGFR M+ cells in vitro, and produced greater tumor shrinkage in EGFR M+ xenografts in vivo. Together, our findings suggest that adding chloroquine to EGFR and AKT inhibition has the potential to improve tumor responses in EGFR M+ NSCLC, and that selective targeting of AKT2 may provide a new treatment option in NSCLC.

DOI: 10.18632/oncotarget.2017
PubMed: 24946858


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:24946858

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.</title>
<author>
<name sortKey="Bokobza, Sivan M" sort="Bokobza, Sivan M" uniqKey="Bokobza S" first="Sivan M" last="Bokobza">Sivan M. Bokobza</name>
<affiliation wicri:level="4">
<nlm:affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford</wicri:regionArea>
<placeName>
<settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author>
<name sortKey="Jiang, Yanyan" sort="Jiang, Yanyan" uniqKey="Jiang Y" first="Yanyan" last="Jiang">Yanyan Jiang</name>
</author>
<author>
<name sortKey="Weber, Anika M" sort="Weber, Anika M" uniqKey="Weber A" first="Anika M" last="Weber">Anika M. Weber</name>
</author>
<author>
<name sortKey="Devery, Aoife M" sort="Devery, Aoife M" uniqKey="Devery A" first="Aoife M" last="Devery">Aoife M. Devery</name>
</author>
<author>
<name sortKey="Ryan, Anderson J" sort="Ryan, Anderson J" uniqKey="Ryan A" first="Anderson J" last="Ryan">Anderson J. Ryan</name>
<affiliation wicri:level="4">
<nlm:affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford</wicri:regionArea>
<placeName>
<settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24946858</idno>
<idno type="pmid">24946858</idno>
<idno type="doi">10.18632/oncotarget.2017</idno>
<idno type="wicri:Area/PubMed/Corpus">000289</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000289</idno>
<idno type="wicri:Area/PubMed/Curation">000289</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000289</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000299</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000299</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.</title>
<author>
<name sortKey="Bokobza, Sivan M" sort="Bokobza, Sivan M" uniqKey="Bokobza S" first="Sivan M" last="Bokobza">Sivan M. Bokobza</name>
<affiliation wicri:level="4">
<nlm:affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford</wicri:regionArea>
<placeName>
<settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author>
<name sortKey="Jiang, Yanyan" sort="Jiang, Yanyan" uniqKey="Jiang Y" first="Yanyan" last="Jiang">Yanyan Jiang</name>
</author>
<author>
<name sortKey="Weber, Anika M" sort="Weber, Anika M" uniqKey="Weber A" first="Anika M" last="Weber">Anika M. Weber</name>
</author>
<author>
<name sortKey="Devery, Aoife M" sort="Devery, Aoife M" uniqKey="Devery A" first="Aoife M" last="Devery">Aoife M. Devery</name>
</author>
<author>
<name sortKey="Ryan, Anderson J" sort="Ryan, Anderson J" uniqKey="Ryan A" first="Anderson J" last="Ryan">Anderson J. Ryan</name>
<affiliation wicri:level="4">
<nlm:affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford</wicri:regionArea>
<placeName>
<settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Oncotarget</title>
<idno type="eISSN">1949-2553</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Apoptosis (drug effects)</term>
<term>Autophagy (drug effects)</term>
<term>Blotting, Western</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (genetics)</term>
<term>Carcinoma, Non-Small-Cell Lung (metabolism)</term>
<term>Cell Line, Tumor</term>
<term>Cell Proliferation (drug effects)</term>
<term>Cell Survival (drug effects)</term>
<term>Chloroquine (administration & dosage)</term>
<term>Chloroquine (pharmacology)</term>
<term>Drug Synergism</term>
<term>ErbB Receptors (antagonists & inhibitors)</term>
<term>ErbB Receptors (genetics)</term>
<term>ErbB Receptors (metabolism)</term>
<term>Female</term>
<term>Gefitinib</term>
<term>Heterocyclic Compounds, 3-Ring (administration & dosage)</term>
<term>Heterocyclic Compounds, 3-Ring (pharmacology)</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (genetics)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Mutation</term>
<term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term>
<term>Proto-Oncogene Proteins c-akt (genetics)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Quinazolines (administration & dosage)</term>
<term>Quinazolines (pharmacology)</term>
<term>RNA Interference</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Apoptose ()</term>
<term>Autophagie ()</term>
<term>Carcinome pulmonaire non à petites cellules (génétique)</term>
<term>Carcinome pulmonaire non à petites cellules (métabolisme)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Chloroquine (administration et posologie)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Composés hétérocycliques 3 noyaux (administration et posologie)</term>
<term>Composés hétérocycliques 3 noyaux (pharmacologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Interférence par ARN</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation</term>
<term>Prolifération cellulaire ()</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term>
<term>Protéines proto-oncogènes c-akt (génétique)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Quinazolines (administration et posologie)</term>
<term>Quinazolines (pharmacologie)</term>
<term>Récepteurs ErbB (antagonistes et inhibiteurs)</term>
<term>Récepteurs ErbB (génétique)</term>
<term>Récepteurs ErbB (métabolisme)</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
<term>Survie cellulaire ()</term>
<term>Synergie des médicaments</term>
<term>Technique de Western</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Tumeurs du poumon (génétique)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Chloroquine</term>
<term>Heterocyclic Compounds, 3-Ring</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>ErbB Receptors</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Chloroquine</term>
<term>Composés hétérocycliques 3 noyaux</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Protéines proto-oncogènes c-akt</term>
<term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Apoptosis</term>
<term>Autophagy</term>
<term>Cell Proliferation</term>
<term>Cell Survival</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>ErbB Receptors</term>
<term>Lung Neoplasms</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>ErbB Receptors</term>
<term>Lung Neoplasms</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Chloroquine</term>
<term>Composés hétérocycliques 3 noyaux</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Chloroquine</term>
<term>Heterocyclic Compounds, 3-Ring</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Blotting, Western</term>
<term>Cell Line, Tumor</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Gefitinib</term>
<term>Humans</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Mutation</term>
<term>RNA Interference</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Apoptose</term>
<term>Autophagie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Interférence par ARN</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation</term>
<term>Prolifération cellulaire</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
<term>Survie cellulaire</term>
<term>Synergie des médicaments</term>
<term>Technique de Western</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the responses are usually incomplete. In this study we show that AKT inhibition, most importantly AKT2 inhibition, synergises with EGFR TKI inhibition to increase cell killing in EGFR M+ NSCLC cells. However, our data also suggest that the synergistic pro-apoptotic effects may be stunted due to a prosurvival autophagy response induced by AKT inhibition. Consequently, inhibiting autophagy with chloroquine significantly enhanced tumor cell death induced by gefitinib and AKT inhibitors in EGFR M+ cells in vitro, and produced greater tumor shrinkage in EGFR M+ xenografts in vivo. Together, our findings suggest that adding chloroquine to EGFR and AKT inhibition has the potential to improve tumor responses in EGFR M+ NSCLC, and that selective targeting of AKT2 may provide a new treatment option in NSCLC. </div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">24946858</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>10</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1949-2553</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>5</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Oncotarget</Title>
<ISOAbbreviation>Oncotarget</ISOAbbreviation>
</Journal>
<ArticleTitle>Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4765-78</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the responses are usually incomplete. In this study we show that AKT inhibition, most importantly AKT2 inhibition, synergises with EGFR TKI inhibition to increase cell killing in EGFR M+ NSCLC cells. However, our data also suggest that the synergistic pro-apoptotic effects may be stunted due to a prosurvival autophagy response induced by AKT inhibition. Consequently, inhibiting autophagy with chloroquine significantly enhanced tumor cell death induced by gefitinib and AKT inhibitors in EGFR M+ cells in vitro, and produced greater tumor shrinkage in EGFR M+ xenografts in vivo. Together, our findings suggest that adding chloroquine to EGFR and AKT inhibition has the potential to improve tumor responses in EGFR M+ NSCLC, and that selective targeting of AKT2 may provide a new treatment option in NSCLC. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bokobza</LastName>
<ForeName>Sivan M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Yanyan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weber</LastName>
<ForeName>Anika M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Devery</LastName>
<ForeName>Aoife M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ryan</LastName>
<ForeName>Anderson J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Headington, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MC_PC_12006</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Oncotarget</MedlineTA>
<NlmUniqueID>101532965</NlmUniqueID>
<ISSNLinking>1949-2553</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C548887">MK 2206</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494921">AKT2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S65743JHBS</RegistryNumber>
<NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>5</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24946858</ArticleId>
<ArticleId IdType="pii">2017</ArticleId>
<ArticleId IdType="pmc">PMC4148097</ArticleId>
<ArticleId IdType="doi">10.18632/oncotarget.2017</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Mol Cancer Ther. 2012 Jan;11(1):154-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22057914</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2011 Dec;2(12):1302-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22185891</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer J. 2009 Sep-Oct;15(5):374-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19826356</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Discov Today. 2003 Dec 15;8(24):1104-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14678733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2008 Jan;118(1):79-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18097482</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioorg Med Chem. 2006 May 1;14(9):3218-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16413786</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2011 Apr 14;30(15):1812-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21242979</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2014 Jan 15;5(1):173-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24368422</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Agric Food Chem. 2009 Oct 28;57(20):9809-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19799425</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2012 Dec;3(12):1600-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23307622</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2013 Feb 15;19(4):833-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23258740</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16968952</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2010 May 25;102(11):1555-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20502460</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biol. 2005 Dec 19;171(6):1023-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16365168</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Enzyme Regul. 1984;22:27-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6382953</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2011 Feb 15;17(4):654-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21325294</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Signal. 2006 Dec;18(12):2262-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16839745</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Respir J. 2001 Dec;18(6):1059-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11829087</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biochem Sci. 2004 May;29(5):233-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15130559</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2000 Nov 1;19(21):5720-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11060023</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Cancer. 2010 Jan;1(1):40-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20811583</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioorg Med Chem Lett. 2008 Jan 1;18(1):49-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18054229</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Death Differ. 2009 Jul;16(7):984-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19424283</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Feb 24;352(8):786-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15728811</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Sci. 2011 Oct;102(10):1822-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21722267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Jun 4;304(5676):1497-500</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15118125</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 2005 Jan 15;385(Pt 2):399-408</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15456405</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Biol Ther. 2010 Apr 1;9(7):493-503</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20139722</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15329413</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Pharmacol Toxicol. 2004;44:195-217</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14744244</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2011 Aug;32(8):1279-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21625009</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2004 May 20;350(21):2129-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15118073</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2013 Dec;4(12):2430-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24280348</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hematol J. 2004;5(1):61-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14745432</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 2003 Mar 17;1603(2):113-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12618311</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2007 Jun 29;129(7):1261-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17604717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2013 Sep 12;154(6):1269-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24034250</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Med Sci. 2011;56(2):275-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22037177</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2013 Sep;81(3):354-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23769318</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Signal. 2011 Dec;23(12):1952-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21777670</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Carcinog. 2010 Apr;49(4):353-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20358631</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Jan 15;70(2):440-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20068163</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2003 Jan 1;63(1):196-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12517798</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2010 Jul;9(7):1956-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20571069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21296855</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2009 Sep 3;361(10):947-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19692680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Dec 10;29(35):4688-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22025163</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2011;6(9):e25255</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21966470</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 2007 Jun 1;21(11):1367-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17510285</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2011;6(1):e14614</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21297943</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2013 Jan 1;73(1):3-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23288916</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
<region>
<li>Angleterre</li>
<li>Oxfordshire</li>
</region>
<settlement>
<li>Oxford</li>
</settlement>
<orgName>
<li>Université d'Oxford</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Devery, Aoife M" sort="Devery, Aoife M" uniqKey="Devery A" first="Aoife M" last="Devery">Aoife M. Devery</name>
<name sortKey="Jiang, Yanyan" sort="Jiang, Yanyan" uniqKey="Jiang Y" first="Yanyan" last="Jiang">Yanyan Jiang</name>
<name sortKey="Weber, Anika M" sort="Weber, Anika M" uniqKey="Weber A" first="Anika M" last="Weber">Anika M. Weber</name>
</noCountry>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Bokobza, Sivan M" sort="Bokobza, Sivan M" uniqKey="Bokobza S" first="Sivan M" last="Bokobza">Sivan M. Bokobza</name>
</region>
<name sortKey="Ryan, Anderson J" sort="Ryan, Anderson J" uniqKey="Ryan A" first="Anderson J" last="Ryan">Anderson J. Ryan</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000299 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24946858
   |texte=   Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24946858" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021